MetaCap

Aldeyra Therapeutics (ALDX) vs Citius Oncology (CTOR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Citius Oncology (CTOR) has outperformed Aldeyra Therapeutics (ALDX) over the past year, losing 55.4% versus a loss of 83.1%. Citius Oncology is the larger company by market cap ($53.2 million vs $50.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALDX-83.06%CTOR-55.44%
+52%-22%-95%
Nov 21, 20251 yearNov 20, 2026
ALDX-86.32%CTOR-95.01%
+321%+103%-115%
Dec 5, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALDX versus CTOR key metrics
MetricALDXCTOR
Share price$0.84$0.5035
Market cap$50.70M$53.25M
1-day change+16.39%-10.95%
YTD return-83.78%-49.65%
1-year return-83.06%-55.44%
5-year return-89.06%—
EPS (TTM)$-0.31$-0.48
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-33.85M$-24.76M
52-week high$5.93$1.83
52-week low$0.527$0.491
Distance from 52-week high-85.83%-72.49%
Analyst consensusstrong_buynone
Avg. price target upside+685.71%+694.44%
Average volume1.16M114.02K
Shares outstanding60.36M105.76M
Employees6—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CTOR has outperformed ALDX by 27.6 percentage points over the past year.

About Aldeyra Therapeutics

ALDX stock →

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

About Citius Oncology

CTOR stock →

Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies.

Health Care · Biotechnology: Pharmaceutical Preparations

ALDX vs CTOR FAQ

Which is bigger, Aldeyra Therapeutics or Citius Oncology?

Citius Oncology (CTOR) is larger, with a market capitalization of $53.25M compared with $50.70M for Aldeyra Therapeutics (ALDX).

Which stock has performed better over the past year, ALDX or CTOR?

CTOR returned -55.44% over the past 12 months, compared with -83.06% for ALDX (price return, excluding dividends). Past performance does not predict future results.

Are Aldeyra Therapeutics and Citius Oncology in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons